Temporal variation of tryptase and interlaboratory variability

Ritter, Shaunah; Fowler, Joshua K.; Lieberman, Jay

doi:10.1016/j.anai.2022.07.025

Cited by 4 publications

(1 citation statement)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Improving the clinical performance of serum tryptase determination is still a hot topic, addressed by numerous studies over the last two years by means of alternative algorithms for perioperative drug hypersensitivity [31,44 ▪▪ ], studies of tryptase reference values in population with different genetic backgrounds and lifestyles [37,45], mathematical approaches for establishing reference values [45], addressing intraindividual variations in bST over time [44 ▪▪ ,46], and finally incentivizing the systematic search of HαT in individuals with bST at 8 μg/l or higher [7,22,47,48 ▪ ].…”

Section: Serum Tryptase and Drug Hypersensitivity: What Is Next?mentioning

confidence: 99%

Serum tryptase and drug hypersensitivity: why, how and what? A systematic review

Klingebiel

Belhocine

Vitte

2023

Current Opinion in Allergy &Amp; Clinical Immunology

View full text Add to dashboard Cite

Purpose of review Serum tryptase, a mast cell marker, provides clues for the mechanism, severity, and management of drug hypersensitivity induced by immunoglobulin E dependent or independent mast cell activation. Recent findings The interpretation of serum tryptase levels has been challenged during the last 2 years by major advances in tryptase genetics and their rapid incorporation into clinical practice. On the contrary, new pathophysiological insight into nonmast cell-dependent immediate hypersensitivity has been gained. Summary This review provides up-to-date information on the pathophysiology and recommended use and interpretation of tryptase in the context of drug hypersensitivity reactions as a function of their endotype.

show abstract